Aytu BioPharma

Aytu BioScience is a specialty healthcare company concentrating on developing products for redox-modulated conditions with a focus on urological indications and related conditions. Aytu BioScience is initially concentrating on male sexual dysfunction and male infertility and will seek expansion opportunities in other urological indications.

Jarrett Disbrow

Executive Vice President, Corporate Operations

3 past transactions

Neos Therapeutics

Acquisition in 2020
The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs. Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Worth area.

Innovus Pharmaceuticals

Acquisition in 2019
Innovus Pharma (INNV) is an emerging pharmaceutical company that develops, in-licenses, acquires, and markets prescription and consumer health products in dermatology, autoimmune, respiratory, and sexual dysfunction diseases with unique packaging and presentation for better patient compliance, convenience and results. Headquartered in San Diego, California, Innovus Pharma was founded in 2011.

Nuelle

Acquisition in 2017
Nuelle is a sexual wellness and intimate care company focused on delivering groundbreaking solutions made specifically for women. It marries its experience in healthcare solutions, consumer products, and technology with a deep understanding of women’s unfulfilled needs. From inception, Nuelle has taken a holistic view of these needs and desires. They worked closely with thought leaders and experts in women’s sexual medicine and wellness including physicians, sex therapists, physical therapists, and psychologists. Together we developed insights that allow Nuelle to translate its scientific approach to understanding.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.